Glaxo's data on blood-clotting drug fails to impress FDA

GlaxoSmithKline's study of Promacta does not provide "robust" evidence that the proposed drug works better than placebos in reducing bleeding in patients with chronic idiopathic thrombocytopenic purpura, the FDA announced Wednesday. GSK and partner Ligand Pharmaceuticals declined to comment on the findings, which are set to be reviewed by an expert panel Friday.

View Full Article in:

Forbes · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL